A Canadian gold project developer and a U.S. bank holding company both received analyst upgrades, one of which has an implied upside of nearly 50%.
| Company Name | Exchange | Ticker | Last Price | Market Cap | Recommendation | Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Medical Facilities Corp | TSX | DR | 19.06 | 596.9 | Upgrade to buy from hold | Timothy Stanish | EVA Dimensions | NA | NA |
| Painted Pony Petroleum Ltd | TSX | PPY | 9.39 | 933.2 | Upgrade to outperform from sector perform | Michael Harvey | RBC Capital Markets | 15.00 | 59.7% |
| Great Prairie Energy Services Inc | TSXV | GPE | 0.20 | 23.7 | Downgrade to hold from buy | John Bereznicki | Canaccord Genuity Corp | 0.40 | 100.0% |
| Penn West Petroleum Ltd | TSX | PWT | 3.81 | 1,894.8 | Downgrade to sector underperform from sector perform | Patrick Bryden | Scotia Capital | 4.25 | 11.5% |
EVA Dimensions upgraded Medical Facilities Corp (TSX: DR), engaged in the business of owning controlling interests in specialty surgical hospitals and ambulatory surgery centers, to buy from hold. The rating company has not provided its target price for the company’s stock.
Painted Pony Petroleum Ltd (TSX: PPY), engaged in acquiring interests in oil and natural gas exploration projects in Canada, was upgraded by RBC Capital Markets to outperform from sector perform with a price target of C$15.00, indicating an upside potential of 59.7% from current levels.
Great Prairie Energy Services Inc (TSXV: GPE), engaged in the business of servicing oil and gas activity in Saskatchewan and Alberta, was downgraded by Canaccord Genuity Corp to hold from buy by reducing its price target to C$0.40 from C$0.50, implying an upside potential of 100.0% from current levels.
Scotia Capital downgraded Penn West Petroleum Ltd (TSX: PWT), engaged in the exploration of oil and natural gas, to sector underperform from sector perform by reducing its price target to C$4.25 from C$6.50, indicating an upside of 11.5% from current levels.
| Company Name | Exchange | Ticker | Last Price | Market Cap | Recommendation | Analyst Name | Rating Company | Target Price |
Upside/ Downside (%) |
|---|---|---|---|---|---|---|---|---|---|
| Superior Energy Services Inc | NYSE | SPN | 19.60 | 2,982.6 | Upgrade to outperform from in-line | Scott Levine | Imperial Capital LLC | 28.00 | 42.9% |
| Boardwalk Pipeline Partners LP | NYSE | BWP | 16.76 | 4,076.4 | Upgrade to buy from neutral | Shneur Z Gershuni | UBS | 21.00 | 25.3% |
| TreeHouse Foods Inc | NYSE | THS | 83.75 | 3,544.9 | Upgrade to outperform from market perform | Amit Sharma | BMO Capital Markets | 95.00 | 13.4% |
| YY Inc | NASDAQ | YY | 70.37 | 3,981.6 | Initiate with buy | Ashley Sheng | SWS Research Co Ltd | 13.16 | -81.3% |
| Avanir Pharmaceuticals Inc | NASDAQ | AVNR | 16.92 | 3,215.3 | Downgrade to hold from buy | Alethia Young | Deutsche Bank | 17.00 | 0.5% |
Imperial Capital LLC upgraded Superior Energy Services Inc (NYSE: SPN), engaged in the business of providing drilling, completion and production related needs of oil and gas companies, to outperform from in line with a price target of $28.00, indicating an upside of 42.9% from current levels.
Boardwalk Pipeline Partners LP (NYSE: BWP), engaged in the business of transporting, gathering and storing natural gas, was upgraded by UBS to buy from neutral with a price target of $21.00, indicating an upside potential of 25.3% from current levels.
BMO Capital Markets upgraded TreeHouse Foods Inc (NYSE: THS), engaged in the business of servicing food primarily to the retail grocery and foodservice distribution channels, to outperform from market perform by raising its price target to $95.00 from $90.00, indicating an upside of 13.4% from current levels.
SWS Research Co Ltd initiated coverage on YY Inc (NASDAQ: YY), engaged in making users engage in real-time online group activities through voice, text and video through communication social platform, with a buy rating assigning a 12-month price target of $13.16, indicating a downside of 81.3% from current levels.
Avanir Pharmaceuticals Inc (NASDAQ: AVNR), engaged in developing and commercializing therapeutic products for the treatment of central nervous system disorders, was downgraded by Deutsche Bank to hold from buy with a price target of $17.00, implying an upside potential of 0.5% from current levels.
